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Abstract
Methylation of the O(6)-Methylguanine-DNA methyltransferase (MGMT) promoter is predictive for treatment response
in glioblastoma patients. However, precise predictive cutoff values to distinguish “MGMT methylated” from “MGMT
unmethylated” patients remain highly debated in terms of pyrosequencing (PSQ) analysis. We retrospectively analyzed
a clinically and molecularly very well-characterized cohort of 111 IDH wildtype glioblastoma patients, who underwent
gross total tumor resection and received standard Stupp treatment. Detailed clinical parameters were obtained.
Predictive cutoff values for MGMT promoter methylation were determined using ROC curve analysis and survival
curve comparison using Log-rank (Mantel-Cox) test. MGMT status was analyzed using pyrosequencing (PSQ), semi-
quantitative methylation specific PCR (sqMSP) and direct bisulfite sequencing (dBiSeq). Highly methylated (> 20%)
MGMT correlated with significantly improved progression-free survival (PFS) and overall survival (OS) in our cohort.
Median PFS was 7.2 months in the unmethylated group (UM, < 10% mean methylation), 10.4 months in the low
methylated group (LM, 10-20% mean methylation) and 19.83 months in the highly methylated group (HM, > 20%
mean methylation). Median OS was 13.4 months for UM, 17.9 months for LM and 29.93 months for HM. Within the LM
group, correlation of PSQ and sqMSP or dBiSeq was only conclusive in 51.5% of our cases. ROC curve analysis revealed
superior test precision for survival if additional sqMSP results were considered (AUC = 0.76) compared to PSQ (cutoff
10%) alone (AUC = 0.67). We therefore challenge the widely used, strict PSQ cutoff at 10% which might not fully reflect
the clinical response to alkylating agents and suggest applying a second method for MGMT testing (e.g. MSP) to
confirm PSQ results for patients with LM MGMT levels if therapeutically relevant.
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Introduction
Glioblastoma (GBM) is the most common and most ag-
gressive primary brain tumor. The histological examin-
ation of neurosurgical tumor specimens as well as the
immmunohistochemical or molecular determination of
the IDH1/2 status remain the gold standard for diagnosis
of GBM [13]. Despite aggressive therapy, the survival of
patients with GBM is approximately 15-17 months [21].
The current standard GBM therapy usually consists of
neurosurgical resection, radiotherapy and additional
chemotherapy with temozolomide (TMZ), an alkylating
agent. But, chemosensitivity to TMZ strongly depends
on epigenetic silencing by methylation of the O(6)-
Methylguanine-DNA methyltransferase (MGMT) pro-
moter [15]. Different randomized trials have shown that
methylation of the MGMT promoter in GBM patients is
associated with significantly higher survival rates if
treated with radiotherapy and TMZ [4]. At the stage of
recurrent disease, a TMZ rechallenge seems only reason-
able in patients with clear methylation of the MGMT
promoter based on the results of the DIRECTOR trial
[24]. Recent data from the NOA-09 trial showed that
newly diagnosed GBM patients with methylated MGMT
promoter might benefit from a more intense first-line
treatment regimen with CCNU in combination with
TMZ [8], accepting an increased toxicity for an im-
proved prognosis. These trials emphasize the importance
of reliable MGMT status assessment and the need for
predictive cutoff levels for clinical decision-making.
The methylation status of the MGMT promoter is
widely determined by quantitative pyrosequencing (PSQ)
[12, 28]. PSQ analysis uses a defined cutoff value to clas-
sify cases as “methylated” or “unmethylated” [1]. In
many neurooncological centers, the biological cutoff is
10% [27]. However, a very strict cutoff value might not
fully reflect the clinical response to TMZ therapy. Vari-
ous previous studies that focused on the technical
assessment of the MGMT status have suggested higher
predictive cutoff levels above 10% [14, 17, 18].
Here, we aimed to determine a predictive cutoff level
for clinical decision-making on the basis of a well-
defined patient cohort of 111 IDH wildtype GBM pa-
tients. Three methylation groups were identified, which
showed a very distinct clinical course in terms of PFS
and OS: unmethylated 0-9% (UM), low methylated 10-
20% (LM), and highly methylated > 20% (HM).
Methods and Material
Tissue samples, clinical and patient data
Two hundred ninety patients with newly diagnosed, pre-
viously untreated GBM (WHO grade IV) patients have
been diagnosed between 2010 and 2015 at the Depart-
ments of Neurosurgery and Neuropathology, Charité
Berlin, Germany. GBM diagnosis was confirmed by at
least two experienced neuropathologists after surgical
resection or stereotactic biopsy. According to the
current WHO classification of CNS tumors [13], IDH
mutation status was determined by IDH1 R132H immu-
nohistochemistry (IHC) and bidirectional Sanger se-
quencing of exon 4 of the IDH1 as well as IDH2 gene
for all GBM patients younger than 55 years [13]. Glio-
sarcoma, epithelioid glioblastoma, giant cell glioblastoma
and IDH mutant tumors were excluded. The following
clinical data were assessed: age at diagnosis, Karnofsky
performance status (KPS), tumor localization, extent of
resection and residual tumor volume, type and timing of
adjuvant therapy, second-line therapy at recurrence,
follow-up time, progression-free (PFS) and overall sur-
vival (OS) in months. The extent of tumor resection was
determined by measuring the contrast-enhancing tumor
volume in mm3 on T1-subtraction MRI imaging pre-
and 48 hours postoperatively using the Brainlab iMRI
software (Brainlab AG, Munich, Germany). Gross total
resection (GTR) was defined as residual tumor volume <
2% [22]. PFS was assessed according to RANO criteria
[25]. We identified 205 IDH wildtype GBM patients who
matched the criteria mentioned above. Three long-term
survivors (LTS; OS > 5 years) were identified in our co-
hort. For two LTS cases, DNA was sufficient to perform
a genome-wide methylation analysis (EPIC array) which
confirmed the diagnosis of GBM, IDH wildtype (Add-
itional file 1: Figure S3 and Figure S4).
Ethical statement
This study was conducted according to the ethical princi-
ples of medical research involving human subjects
according to the Declaration of Helsinki. The clinical data
were assessed and anonymized for patients’ confidentiality.
Ethical approval (EA2/064/17) was granted by the institu-
tional ethics board of the Charité Ethics Committee.
DNA extraction, bisulfite treatment and analysis of MGMT
promoter methylation status in tumor samples
Areas of high tumor cell content (≥ 80%) were chosen
and macro-dissected for further analysis (Additional file
1: Figures S1a, dashed line; 1 b). Genomic DNA was ex-
tracted from formalin-fixed and paraffin embedded
(FFPE) samples using the Qiagen DNeasy blood and tis-
sue DNA extraction kit according to the manufacturer´s
protocol (Qiagen, Hilden, Germany). The DNA was so-
dium bisulfite-modified using the EZ DNA Methylation-
Gold™ Kit (Zymo Research, Irvine, CA).
Pyrosequencing (PSQ) Quantitative methylation ana-
lyzes were performed using the PyroMark Q24 MGMT
kit (Qiagen, Hilden, Germany) and an automated Pyro-
Mark Q24 System (Qiagen, Hilden, Germany) following
the manufacturer’s instructions. Data was analyzed with
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the PyroMark Q24 Software 2.0 (Qiagen, Hilden,
Germany). The percentage of methylated alleles was cal-
culated as the mean value of the methylation percentage
obtained. The cutoff value ≥ 10% was defined to classify
MGMT methylated vs. unmethylated cases, which is
commonly used and has been validated for routine clin-
ical diagnostics [27]. Standardized positive and negative
controls were included in every PSQ run. The PSQ re-
sults were evaluated by at least two experienced
neuropathologists.
Semi-quantitative methylation-specific PCR (sqMSP)
sqMSP was performed with primers specific for either
“methylated” or “unmethylated” DNA as previously de-
scribed [5]. Original MSP PCR gels are shown in Add-
itional file 1: Figure S2. Primers and PCR programs are
listed in the methods and material section of Additional
file 1. Semi-quantitative analysis of the optical band in-
tensity (I) was performed using ImageJ (National Insti-
tutes of Health, Bethesda, USA). The following equation
was used:
Band intensity methylated in%
¼ Imeth þ Iunmethð Þ=Imethð Þ  100
Band intensity unmethylated in%
¼ Imeth þ Iunmethð Þ=Iunmethð Þ  100
Direct Bisulfite Sequencing (dBiSeq)
dBiseq was carried out as previously described [16] with
minor adaptations. Primers and PCR program are listed
in the methods and material section of Additional file 1.
Sequencing was performed at Eurofins Genomics, Ebers-
berg, Germany. Sequenced samples were returned as
.ab1 files, which were then analyzed using Chromas [9]
(software program for PC, available at http://www.tech-
nelysium.com.au/chromas.html).
Analysis of MGMT promoter methylation status in
positive and negative controls
Both, positive and negative controls (listed in Additional
file 1: Table S1) were assessed by PSQ, sqMSP, and dBiseq.
Samples of non-neoplastic brain tissue and one samples
with genomic DNA extracted from whole peripheral
blood served as negative controls. The primary cell line
SF126 and 7 tumor samples with clear MGMT promoter
methylation levels > 30% were used as positive controls.
Genome-wide DNA methylation analysis
DNA methylation signature analysis was performed
using the Illumina Infinium Methylation EPIC array as
previously described [2].
IDH1 and IDH2 Sanger sequencing
Bidirectional Sanger sequencing of exon 4 of IDH1 and
IDH2 was performed in IDH R132H IHC-negative or
-equivocal cases in all patients < 55 years of age. PCR
primers for the genomic regions corresponding to IDH1
exon 4 (codon R132) and IDH2 exon 4 (codon R172)
and the flanking intronic sequences are displayed in
the methods and material section of Additional file1. Se-
quencing was performed at Eurofins Genomics, Ebers-
berg, Germany.
Immunohistochemical procedures
Immunohistochemical stainings were performed on a
Benchmark XT autostainer (Ventana Medical Systems,
Tuscon, AZ, USA) with standard antigen retrieval methods
(CC1 buffer, pH8.0, Ventana Medical Systems, Tuscon, AZ,
USA) using 4-μm-thick, FFPE tissue sections (Additional
file 1: Figures S1 c-f). The following primary antibodies
were used: polyclonal rabbit anti-GFAP (1:2000, Dako),
monoclonal mouse anti-MIB1 (Ki-67, 1:100, clone M7240,
Dako), polyconal rabbit anti-ATRX (1:200, Sigma), mouse
monoclonal anti-IDH1 R132H (1:20, clone H09, Dianova).
The iVIEW DAB Detection Kit (Ventana Medical Systems,
Tuscon, AZ, USA) was used according to the manufactur-
er's instructions. Sections were counterstained with
hematoxylin, dehydrated in graded alcohol and xylene,
mounted and coverslipped. IHC stained sections were eval-
uated by two independent, experienced neuropathologists.
When no agreement was reached, the sections were
reviewed by our team of neuropathologists at our depart-
ment (Charité) and further molecular diagnostics (e.g.
IDH1/IDH2 bidirectional Sanger sequencing, genome-wide
DNA methylation analysis (EPIC analysis)) was performed.
Statistical analysis
Statistical analysis was performed in cooperation with the
Charité´s Institute for Biometrics and Clinical Epidemi-
ology using GraphPad Prism 5 (GraphPad Software, La
Jolla, CA, USA). Kaplan-Meier survival curves were ob-
tained and differences in PFS and OS were tested for statis-
tical significance using the log-rank test. Significance level
was set at p < 0.05.
ROC analysis was used for diagnostic test evaluation.
The true positive rate (Sensitivity) was plotted as a func-
tion of the false positive rate (100-Specificity) for different
cutoff points. The area under the ROC curve (AUC) mea-
sured the accuracy. An AUC of 1 represents a perfect test;
0.8-0.9 a good test, 0.7-0.8 a fair test, 0.6-0.7 a poor test,
and an area of ≤ 0.5 represents a worthless test.
Results
Study cohort
Heterogeneity of the patient cohort (e.g. in terms of the
IDH status) has been a major point of criticism in
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previous studies where the predictive mean MGMT pro-
moter methylation cutoff had to be determined. There-
fore, we selected a homogeneous group of IDH wildtype
GBM patients with KPS > 70%, who received i) GTR of
GBM manifestation, ii) Stupp regime within 4-6 weeks
after initial surgery [20], and iii) completed Stupp regime
after 6 cycles or until progression of disease, assessed ac-
cording to the RANO criteria (n=111). All clinical infor-
mation is displayed in Table 1. GBM diagnosis was
confirmed by at least two experienced neuropathologists
using a standardized panel of conventional and immuno-
histochemical stainings (Additional file 1: Figures S1 a-f )
. All cases were proven IDH wildtype by bidirectional
Sanger sequencing. Patients with IDH1 (Additional file
1: Figures S1 g-j) and IDH2 (Additional file 1: Figure S5)
mutant tumors were excluded.
Initially, Kaplan-Meier curves were generated for the
following methylation groups (mean MGMT promoter
methylation): 0-9%, 10-20%, 21-30%, 31-40%, and > 40%
(Figure 1 a, b). mPFS in months was 5.28 (0-9%), 8.03 (10-
20%), 22.4 (21-30%), 16.13 (31-40%), and 13.8 (> 40%).
mOS in months was 10.07 (0-9%), 13.83 (10-20%), 33.33
(21-30%), 29.93 (31-40%), and 19.43 (> 40%). For PFS,
Kaplan-Meier curves comparison revealed significant dif-
ferences between the following groups: 0-9% vs. 10-20%
(*p=0.0143, HR 1.745, CI 1.118 to 2.725), 0-9% vs. 21-30%
(***p<0.0001, HR 3.307, CI1.885 to 5.800; 0-9% vs. 31-
40%), 0-9% vs. 31-40% (***p=0.0002, HR 2.788, CI 1.614 to
4.817), 0-9% vs. > 40% (***p<0.0001, HR 2.869, CI 1.787 to
4.608), and 10-20% vs. > 40% (*p=0.0189, HR 2.109, CI
1.131 to 3.933). For OS, Kaplan-Meier curves comparison
demonstrated significant differences between: 0-9% vs. 10-
20% (*p=0.0239, HR 1.636, CI1.067 to 2.509), 0-9% vs. 21-
30% (***p=0.0003, HR 2.638, CI 1.569 to 4.435), 0-9% vs.
31-40% (**p=0.024, HR 2.252, CI1.332 to 3.805), and 0-9%
vs. > 40% (***p<0.0001, HR 2.478, CI 1.565 to 3.922). Since
PFS and OS were not significantly different in 21-30%, 31-
40%, and > 40%, these groups were combined to one
group (> 20%). A survival curve comparison indicated a
highly significant difference between 0-9% and > 20%
mean MGMT methylation in terms of PFS and OS. Con-
sequently, we introduced three major methylation groups:
unmethylated 0-9% (UM), low methylated 10-20% (LM)
and highly methylated > 20% (HM, Figure 1 c, d). mPFS
was 7.2 months in the UM group, 10.4 months in the LM
group and 19.83 months in the HM group. Kaplan-Meier
curve comparison revealed significant differences between
UM vs. LM (**p= 0.0046, HR 2.225, CI 1.280 to 3.869),
LM vs. HM (*p=0.0104, HR 4.224, CI 2.443 to 7.303), and
UM vs. HM (***p< 0.0001, HR 2.439, CI 1.233 to 4.826).
mOS was 13.4 months in the UM group vs. 17.9 months
in the LM group vs. 29.93 months in the HM group. Sur-
vival differences were not significant for UM vs. LM (p=
NS, HR 1.619, CI 0.9780 to 2.680) and for LM vs. HM (p=
NS, HR 1.619, CI 0.9780 to 2.680), which was due to one
LTS patients within the LM group. OS was significantly
different between UM vs. HM (***p< 0.0001, HR 2.900, CI
1.816 to 4.630).
Defining a transition zone
LM patients demonstrated a similar clinical course com-
pared to UM patients in terms of PFS and OS, which in-
dicated that the widely used PSQ cutoff of 10% does not
fully reflect the clinical response to alkylating agents.
We have therefore defined the LM group (10-20%) as a
“transition zone” between unmethylated and clearly
methylated cases. To validate the PSQ MGMT results in
this particular subgroup of the unselected study cohort,
these cases (LM, n=35) were additionally analyzed by
sqMSP (n=32/35). In 53.1 % (n=17/32) sqMSP and PSQ
results were disconcordant (representative MSP and
PSQ results are shown in Figures 2 c, d). For n=22/35
Table 1 Patients’ characteristics of our study cohort
Study cohort n=111 n %
Gender Female 48 43
Male 63 57
Age in years Mean 58.9 -
Median 61.2 -
Range 18-85.4 -
MGMT Meth. (mean ≥10%) 56 51
Unmeth. (mean < 10%) 55 49
Toxicity during 1st line therapy CTG °III-IV 4 4
2nd line therapy mTMZ 38 34






Follow up in months Mean 19.4 -
Median 15.4 -
Range 0.3-90 -
Lost to follow up 2 2
PFS in months Mean 12 -
Median 7.8 -
Range 0.3-56 -
OS in months Mean 19.8 -
Median 15.5 -
Range 0.5-90 -
BEV bevacizumab, CCNU lomustin, CTG common toxicity criteria, GTR gross
total resection, MGMT O6-methylguanine-DNA-methyltransferase, meth
methylated, mTMZ metronomic temozolomide, OS overall survival, PR partial
resection, TMZ temozolomide, TTFields tumor treating
fields, unmeth unmethylated
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cases, additional dBiseq data was available (representa-
tive results in Fig. 2e). PSQ and dBiseq showed identical
results in only 45.5% (n=10/22), MSP and dBiseq in 90%
(n=18/20) of cases. The detailed results are displayed in
Additional file 1: Table S1. In general, in cases with PSQ
≥ 16%, we observed a very high consistency between
PSQ, MSP and dBiseq results.
We additionally investigated the survival profiles of all
transition zone patients after combining PSQ and MSP
results. First, we redistributed the LM patients to either
the UM or HM category based on MSP testing. As ex-
pected, the differences between UM vs. HM were highly
significant: PFS (***p<0.0001, HR 3.002, CI 1.886 to
4.778) and OS (***p<0.0001, HR 2.629, CI 1.729 to 3.997,
Additional file 1: Figure S6 a, b). Next, we defined the
following more detailed four groups to investigate if the
integration of MSP resulted in a redistribution of LM
patients to either the UM or HM category: UM, LM +
MSP unmethylated, LM + MSP methylated, and HM.
The results still clearly indicated a transition zone for
median PFS and OS, which seemed independent of the
MSP results (Additional file 1: Figure S6 c, d). Moreover,
curve comparison between PSQ LM + MSP unmethy-
lated and PSQ LM + MSP methylated showed no signifi-
cant difference, most likely due to small sample size and
presence of one LTS patients within the LM group.
Regarding the aforementioned results, we performed
ROC curve analysis for prognostic test evaluation for
PSQ (cutoff 10%) alone and for PSQ (cutoff 10%) com-
bined with sqMSP results. LM cases that were consid-
ered MGMT unmethylated by sqMSP were therefore
assigned to the UM group, LM cases that were consid-
ered MGMT methylated by sqMSP were therefore
assigned to the HM group. ROC curve analysis revealed
superior test precision with an AUC = 0.76 for PSQ
(cutoff 10%) combined with sqMSP results compared to
PSQ (cutoff 10%) alone (AUC = 0.67; Figure 2 a). Add-
itionally, we performed step-wise cutoff testing for 10%,
12%, 15%, 17%, and 20% PSQ results. At a cutoff of 17%,
highest test precision was reached with an AUC of 0.77
(Figure 2 b).
Discussion
We demonstrate that IDH wildtype GBM patients with
low methylation of the MGMT promoter (mean 10-20%)
represent a “transition zone” in terms of PFS and OS com-
pared to clearly unmethylated (0-9%) and highly methyl-
ated (> 20%) patients. For patients with low methylated
MGMT promoter (10-20%), PSQ results could be vali-
dated in only 51.5 % (n=17/33 samples, Additional file 1:
Table S1) by one other method (sqMSP or dBiseq) to be
clearly methylated.
Both, MSP and PSQ, have independently been suggested
as the “gold standard” for methylation analysis of the
MGMT gene promoter [3, 11]. As to which method to use,
the scientific community has not reached a consensus yet
Fig. 1 a, b: Kaplan-Meier curves for progression-free (PFS) and overall survival (OS) of subgroup analysis comparing the different methylation groups
(mean MGMT promoter methylation): 0-9%, 10-20%, 21-30%, 31-40%, and > 40%. c, d: Kaplan-Meier curves for progression-free (PFS) and overall
survival (OS) of subgroup analysis comparing the different methylation groups UM, LM, and HM according to mean MGMT methylation PSQ results
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[3, 19]. Several studies have demonstrated the prognostic
value of MSP. Nevertheless, MSP primers are generated to
detect either unmethylated or fully methylated MGMT pro-
moter sites, which may in turn result in a lower sensitivity
of this method [10]. Furthermore, MSP lacks international
standardization [19]. In contrast to MSP, PSQ provides in-
formation about the extent of methylation at each individ-
ual CpG site, which improves the sensitivity of analyzing
heterogeneous methylation patterns within a tumor sample
[10]. Nevertheless, the optimal cutoff value is still a matter
of scientific debate [1]. The predictive cutoff is strongly in-
fluenced by i) interlaboratory differences, ii) technical chal-
lenges of MGMT testing, which are strongly dependent on
successful bisulfite treatment of the DNA [6], and particu-
larly iii) tissue processing, such as formalin-fixation and
paraffin-embedding [17, 18]. Therefore, determining a “grey
zone” seems to be a more reasonable approach than setting
a very strict cutoff.
Fig. 2 a: Receiver operating characteristics (ROC) for 10% PSQ cutoff (AUC = 0.67) and 10% PSQ cutoff corrected for sqMSP results (AUC = 0.76) in terms
of overall survival. b: Receiver operating characteristics (ROC) for determination of optimal cutoff values for PSQ results at 10% (AUC = 0.67), 12%
(AUC = 0.72), 15% (AUC = 0.74), 17% (AUC = 0.77) and 20% (AUC = 0.75). c: Representative methylation-specific PCR (MSP) shows results obtained from 15
different, representative GBM samples and one negative control (NC). The DNA was extracted from formalin-fixed and paraffin-embedded tissue.
Methylated samples demonstrated PCR products with primers detecting the methylated (M, 89bp) and unmethylated (U, 93bp) MGMT promoter
sequence. Clearly unmethylated samples showed PCR products only for the unmethylated MGMT promoter sequence (U). The pyrogram (d) demonstrates
the pyrosequencing result of patient #19 (PSQ mean = 14%). The yellow areas correspond to the internal control of conversion (arrows). The blue areas
indicate the polymorphism (T/C) as result of the bisulfite treatment and show the level of the methylation (%) of each CpG. An exemplary section of
direct Bisulfite Sanger sequencing trace (forward) of patient #26 demonstrates CpGs 13-18 of 27 (arrows) which are partly (T/C) or fully converted (e)
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Even though previous studies have identified 10% as
the PSQ cutoff to distinguish methylated from unmethy-
lated samples - often based on biological determinants
comparing non-neoplastic to neoplastic tissue [4, 17, 27,
28] - several more recent studies have suggested to
introduce a “transition” or “grey zone” [7, 17, 18, 26] for
partly methylated tumors that perhaps cannot be
assigned to either the methylated or unmethylated cat-
egory. Many of these studies were criticized due to small
sample size and heterogeneous patient population [28]
including different therapeutic regimens and IDH mu-
tant as well as IDH wildtype GBM patients.
Seeing that IDH mutant GBMs demonstrate a hyper-
methylator phenotype and show a favorable clinical
course, the impact of MGMT methylation on survival
may have been overestimated in those studies [23].
Clearly, our study also has some limitations that re-
strict the interpretation of our data. There are both, the
retrospective character and the single center experience.
Nevertheless, a key advantage of this study is that it pro-
vides a large data set (n=111) from a both clinically and
molecularly very well-documented and characterized
subgroup of IDH wildtype GBM patients (according to
the most recent WHO classification).
As the different methylation groups demonstrate a
very distinct clinical course in terms of PFS and OS, and
PSQ and sqMSP/sBiseq results are only concordant in
51.5% of LM patients - which might partly be explained
by a heterogeneous methylation pattern and technique-
dependent analysis of different CpG sites within the
MGMT promoter [19] - we conclude that PSQ results
in patients with low MGMT promoter methylation (10-
20%) should be interpreted with caution. If therapeutic-
ally relevant, a second technique, e.g. MSP could be add-
itionally used to substantiate the results in MGMT PSQ
transitional (10-20%) cases. Our ROC curve analysis in-
dicates that the combination of PSQ and MSP results is
diagnostically beneficial in the LM patient cohort. Our
results, furthermore, suggest 17% as the most accurate
cutoff value for PSQ analysis. It has been the consensus
in clinical practice to also treat patients with low level
MGMT methylation as a potential benefit cannot be ex-
cluded. Nevertheless, further scientific investigation is
necessary to establish this efficacy. Especially in elderly
(≥ 70 years) or fragile GBM patients, a further stratifica-
tion would be favorable as these patients have a higher
risk of chemotherapy-related toxicity and demonstrate
less survival benefit from alkylating agents if MGMT is
unmethylated [19]. To conclude, we recommend the fol-
lowing classification system be used (particularly if FFPE
samples are used): clearly unmethylated (< 10%), low
methylated (between 10-20%), and clearly methylated
(> 20%), which correlated with significantly improved
PFS and OS in our cohort.
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Additional file 1: Figure S1. Glioblastoma histology and representative
IDH1 Sanger sequencing results. Figure S2. Original MSP PCR gels.
Figure S3. Methylation profiling report of GBM LTS patient #20 (GBM
#20). Figure S4. Methylation profiling report of GBM LTS patient #14
(GBM #14). Figure S5. IDH2 mutation. Figure S6. Kaplan-Meier curves
for progression-free (PFS) and overall survival (OS) after combining PSQ
and MSP results. Table S1. MGMT PSQ result of subgroup LM (10-20%)
and corresponding sqMSP and dBiseq results. (DOCX 6001 kb)
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